1. Albain KS, Crowley JJ, LeBlanc M. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618–26.
2. Wagner W, Hermann R, Hartlapp J. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenthaerapie und Onkologie 2000; 176: 73–80.
3. Teicher BA, Hulden SA, al-Achi A. Classification of antineoplastic treatments by their differential toxicity towards putative oxygenated and hypoxic tumor subpopulations in vivo in the FSallC murine fibrosarcoma. Cancer Res 1990; 50: 1339–44.
4. Brizel DM, Sibley GS, Prosnitz LR et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38 (2): 285–9.
5. Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Dat Syst Rev 2006; 3: CD003407.
6. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255–60.
7. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708–13.
8. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960–72.
9. Danish Head and Neck Cancer Group website. DAHANCA10 Interim Analysis. Issued: December 2006. Available from: http://conman.au.dk/dahanca/.
10. Amgen Inc. Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy. Available from: http://www.climcalstudyresults.org/documents/company-study_2157_0.pdf.
11. Wright JR. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027–32.
12. Batra S, Perelman N, Luck LR et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003; 83: 1477–87.
13. Dagnon K, Pacary E, Commo F et al. Expression of erythropoietin and erythropoietin receptor in non small cell lung carcinomas. Clin Cancer Res 2005; 11: 993–9.
14. Yasuda Y, Fujita Y, Matsuo T et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24: 1021–9.
15. Arcasoy MO, Amin K, Vollmer RT et al. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2005; 18: 421–30.
16. Eccles TG, Patel A, Verma A et al. Erythropoietin and the erythropoietin receptor are expressed by papillary thyroid carcinoma from children and adolescents. Expression of erythropoietin receptor might be a favorable prognostic indicator. Ann Clin Lab Sci 2003; 33: 411–22.
17. Westphal G, Niederberger E, Blum C et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002; 88: 150–9.
18. Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561–5.
19. Acs G, Zhang PJ, Rebbeck TR et al. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002; 95: 969–81.
20. Acs G, Xu X, Chu C, Acs P et al. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004; 100 (23): 76–86.
21. Yasuda Y, Musha T, Tanaka H et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001; 84: 836–43.
22. Yasuda Y, Fujita Y, Masuda S et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002; 23: 1797–805.
23. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003; 307: 999–1007.
24. Arcasoy MO, Amin K, Karayal AF et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002; 82: 911–8.
25. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000; 58: 647–57.
26. Lai SY, Childs EE, Xi S et al. Erythropoietin mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005; 24: 4442–9.
27. MohyeldinA, Lu H, Dalgard C et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005; 7: 537–43.
28. Selzer E, Wacheck V, Kodym R et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000; 10: 421–6.
29. Berdel WE, Oberberg D, Reufi B et al. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. AnnHematol 1991; 63: 5–8.
30. Elliott S, Busse L, Bass MB et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107 (5): 1892–5.
31. Brown WM, Maxwell P, Graham AN et al. Erythropoietin Receptor Expression in Non-Small Cell Lung Carcinoma: A Question of Antibody Specificity. Stem Cells 2007; 25 (3): 718–22.
32. Hardee ME, Kirkpatrick JP, Shan S et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 2005; 93 (12): 1350–5.
33. Ning S, Hartley C, Molineux G et al. Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. Cancer Res 2005; 65 (1): 284–90.
34. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma. Br J Cancer 2005; 93 (2): 224–32.
35. Information for Healthcare Professionals Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]) Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm

И.А.Покатаев, С.А.Тюляндин

НИИ клинической онкологии РОНЦ им. Н.Н.Блохина РАМН, Москва